FDA proposes new framework prioritizing consistency over flexibility for rare disease drug reviews

The FDA announced a shift in its approach to evaluating rare disease therapies, emphasizing a more uniform assessment process.

Agency officials explained that the flexibility shown over the summer was not intended to become the norm, and that consistency will help ensure fairer decisions.

The proposed framework aims to apply the same criteria across submissions, which could give developers clearer expectations for rare disease drug approvals.